EXEL Share Price

Open 26.88 Change Price %
High 27.33 1 Day 0.24 0.90
Low 26.80 1 Week 0.25 0.93
Close 26.99 1 Month 2.97 12.36
Volume 4711417 1 Year 18.40 214.20
52 Week High 27.63
52 Week Low 8.58
EXEL Important Levels
Resistance 2 27.48
Resistance 1 27.28
Pivot 27.04
Support 1 26.70
Support 2 26.50
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
SCHS 0.05 66.67%
CPWR 4.65 55.00%
LOCM 0.09 50.00%
VRTB 3500.00 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SRPT 40.93 20.10%
AEZS 2.80 19.66%
GEVO 0.71 18.33%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
QKLS 0.11 -47.62%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Exelixis, Inc. (NASDAQ: EXEL)

EXEL Technical Analysis 5
As on 20th Jul 2017 EXEL Share Price closed @ 26.99 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 18.19 & Strong Buy for SHORT-TERM with Stoploss of 22.20 we also expect STOCK to react on Following IMPORTANT LEVELS.
EXEL Target for July
1st Target up-side 28.43
2nd Target up-side 31.09
3rd Target up-side 33.75
1st Target down-side 20.83
2nd Target down-side 18.17
3rd Target down-side 15.51
EXEL Other Details
Segment EQ
Market Capital 726558528.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.exelixis.com
EXEL Address
EXEL
210 East Grand Avenue
South San Francisco, CA 94080
United States
Phone: 650-837-7000
Fax: 650-837-8300
EXEL Latest News
Interactive Technical Analysis Chart Exelixis, Inc. ( EXEL NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Exelixis, Inc.
EXEL Business Profile
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications. The clinical program for cabozantinib is focused on the treatment of metastatic castration-resistant prostate cancer (CRPC) and medullary thyroid cancer but also includes the evaluation of other tumor types. Cabozantinib inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth, vascularization and/or metastasis.